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WE investigated  the  serum  concentrations  of  inter-
leukin-6  (IL-6)  and  two  IL-6  family  of  cytokines
(leukaemia inhibitory factor (LIF) and ciliary neuro-
trophic factor (CNTF) as well as IL-6 soluble receptor
(sIL-6R)  using  an  enzyme-linked  immunosorbent
assay (ELISA) in 66 patients with rheumatoid arthritis
(RA) and 24 healthy controls. We examined a possible
association between the  serum  levels  of  these  pep-
tides and RA activity according to the Mallya and Mace
scoring system and Ritchie’s index. We also evaluated
the correlation between the serum levels of IL-6, LIF,
CNTF  and  sIL-6R  and  duration  of  the  disease  and
calculated sIL-6R/IL-6 ratio in RA patients and in the
control group. IL-6 and sIL-6R were detectable in all
66 patients with RA and 24 normal individuals. LIF
was also found in the serum of all patients with RA
and  in  16  (66.7%)  normal  individuals.  In  contrast
CNTF  was  measurable  only  in  15  (22.7%)  patients
with  RA  and  24  (33.3%)  normal  individuals.  The
highest  IL-6  and  sIL-6R  levels  were  found  in  the
patients with Stages 3 and  4 of  RA  activity and  the
lowest in the control group. In contrast there were no
statistically significant diferences between the LIF and
CNTF levels in RA patients and normal individuals. We
found  positive  correlation  between  IL-6  and  sIL-6R
concentrations and Ritchie’s index and a lack of such
correlation  with  LIF  and  CNTF.  IL-6  serum  level
correlated  positively  with  the disease  duration,  but
sIL-6R, LIF and CNTF did not. Serum sIL-6R/IL-6 ratio
was significantly lower in RA patients than in healthy
controls.  In  conclusion,  an  increase  in  the  serum
levels  of  IL-6  and  sIL-6R,  but  not  LIF  and  CNTF
concentrations,  may  be  useful  markers  for  RA
activity.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease localized preferentially in the synovial joints,
resulting  in  joint  destruction  and  permanent
disability.
1,2
There  is  growing  evidence  suggesting  that  some
cytokines,  particularly  proinflammatory  cytokines
such as tumour necrosis factor a (TNF-a ), interleukin-
1 (IL-1), interferon g (IFN-g ) and interleukin-6 (IL-6),
play  an  important  role  in  the  pathogenesis  of  this
disease.
3,4 These inflammatory cytokines are present
in the rheumatoid synovial membrane and participate
in  cell  proliferation  as  well  as  in  the  synthesis  of
prostaglandins,  metalloproteinases  and  other
cytokines.
5–7
IL-6 is a pleiotropic, immunomodulatory cytokine
produced by a variety of cell types, including fibro-
blasts, endothelial cells, monocytes and both benign
and malignant lymphocytes of B and T cell origin.
8 It
is a multifunctional cytokine, which plays a key role
in the differentiation and growth of haematopoietic
cells,  B-cells,  T-cells,  keratinocytes,  neuronal  cells,
osteoclasts  and  endothelial  cells.
9 Moreover,  IL-6
modulates  the  transcription  of  several  liver-specific
genes during acute inflammatory states. Pertinent to
inflammation  is  the  ability  of  IL-6  to  induce  acute
phase protein synthesis in hepatocytes.
10
IL-6 is a member of a family of cytokines which also
includes leukaemia inhibitory factor (LIF), oncostatin
M  (OSM),  ciliary  neurotrophic  factor  (CNTF),  and
interleukin-11  (IL-11).
11,12 These  cytokines  are  a
group of evolutionary related proteins characterized
by a common tertiary framework, with a distinctive,
four  helix bundle  topology.
13,14 IL-6  type  cytokines
induces growth or differention via a receptor system
that  involves  a  specific  receptor  and  the  use  of  a
shared signalling subunit, gp 130.
15
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Mediators of Inflammation, 7, 347–353 (1998)Cells  isolated  from  the  synovium  of  RA  patients
expressed  mRNA  for  LIF,  OSM  and  IL-11  at  higher
levels  than  did  synovial  cells  from  osteoarthritis
patients,  and  spontaneously  released  greater  quan-
tities of this protein in culture.
16 Elevated levels of LIF ,
OSM and IL-11 were also found in the synovial fluids
of RA patients.
16–18 However OSM, LIF and IL-11 have
been reported to be undetectable in peripheral blood
of  these  patients.
16 To  our  knowledge  the  level  of
CNTF in the serum and synovial fluid of RA patients
has been not investigated, so far. However, we have
found a detectable level of this cytokine in the serum
of the majority of systemic lupus erythematosus (SLE)
patients.
19
The cellular IL-6 receptor complex consists of two
different proteins, an 80-kDa ligand binding glycopro-
tein  (IL-6R)  and  gp  130  involved  in  cellular  signal
transduction.
20 These  two  subunits  of  the  IL-6R
complex are proteolytically cleaved and released from
the cell as soluble receptor proteins.
21 Soluble forms
of the IL-6R (sIL-6R) and gp 130 are found in different
body  fluids  in  patients  with  various  inflammatory
diseases, including SLE and RA.
22,23
In  the  present  study  we  measured  the  serum
concentration of IL-6, LIF , CNTF and sIL-6R in patients
with RA using ELISA assay. We correlated the serum
levels of these proteins with disease activity accord-
ing  to  the  Mallya  and  Mace  scoring  system  and
Ritchie’s index as well as with disease duration and
type of treatment. We also evaluated the correlation
between  the  serum  levels  of  these  three  cytokines
and IL-6R as well as IL-6 with LIF and CNTF .
Patients and methods
Patients
The study involved 66 patients (57 females and nine
males). Their mean age was 51.1 years (range 20–78
years).  They  fulfilled  the  revised  criteria  of  the
American Rheumatism Association (ARA), criteria for
diagnosis of RA.
24,25
The mean duration of their disease was 8.7 years
(range from 1 month to 30 years). Forty-six of them
were found  positive for  the rheumatoid  factor  (RF)
and 20 were negative. Most of the RA patients were
receiving  non-steroidal  anti-inflamatory  drugs
(NSAID). In addition, 26 of the patients were treated
with  prednisone, eight were taking D-pencillamine,
nine-gold salts, eight methotrexate and eight sulfasa-
lazine. On the day of blood sampling, each patient’s
history  was  recorded  and  a  physical  examination
was  performed.  Clinical  variables  included  disease
duration,  applied  treatment  and  a  joint  count  for
pain/tenderness.  Ritchie’s  articular  index  (RI),
26
duration of the morning stiffness and visual analogue
pain score (VAS) were recorded by the same obser-
ver  (A.G.).
Disease  activity  was  scored  during  visits  to  the
outpatient clinic according to the method described
by Mallya and Mace.
27 Our group of patients included
16 patients in Stage 1 or 2, 34 in Stage 3 and 16 in
Stage  4  of  the  disease  activity,  according  to  this
classification. The clinical and laboratory features of
RA patients are presented in Table 1.
The control group consisted of 24 healthy individ-
uals, 19 women and 5 men, aged from 24 to 68 years
(mean  51.2  years).  Each  underwent  a  thorough
physical  examination  performed  by  one  of  the
authors (A.G.).
Laboratory tests
On  the  day  of  blood  sampling  for  cytokines  the
following laboratory parameters were analysed: com-
plete  blood  cell  count  (CBC), Westergren  erythro-
cyte sedimentation  rate (ESR), urinalysis blood urea
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Table 1. Clinical characteristics of patients with rheumatoid
arthritis
Symptom Number of
patients
%
Total 66 100
Age
Mean ± SD 53.6 ± 12.4
Range 20–78
Sex (male/female) 9/57 13.6/86.4
Disease activity according to
Mallya and Mace
Grade 1 1 1.5
Grade 2 15 22.7
Grade 3 34 51.6
Grade 4 16 24.2
Ritchie point index
Mean ± SD 15.2 ± 6.9
Range 1–30
RE positive 44 66.6
Fever 12 18.2
Renal disorder
(creatinine > 1.2mg/dl)
10 15.2
Pulmonary rheumatic disease 2 0.3
Vasculitis lesions 8 12.1
Weight loss (>5kg/6 months) 18 27.3
Treatment during the study
NSAID 48 12.1
Prednisone 24 36.4
Methotrexate 7 10.6
D-penicillamine 8 12.1
Gold salts 8 12.1
Sulfasalazine 9 18.2
Laboratory parameters
ESR
Mean ± SD 54.9 ± 32.2
Range 10–136
Haemoglobin (g/dl)
Mean ± SD 11.9 ± 1.5
Range 7.6 ± 11.9
Platelets (3 109/1)
Mean ± SD 286.4 ± 85.4
Range 152–614
White blood cells (3 109)
Mean ± SD 7.8 ± 1.9
Range 4.8–12.5nitrogen and creatinine levels, fibrinogen level, liver
function  tests (GOT, GPT, bilirubin), C-reactive pro-
tein  (CRP), serum iron  and  rheumatoid  factor (RF).
Chest  radiographs,  abdomen  ultrasonography  and
EKG  were  also  performed.
Serum sampling and cytokine determination
Venous blood samples for IL-6, IL-6 related cytokines
(LIF and CNTF) and sIL-6R were collected at the time
of  clinical  assessment  into  pyrogen  free  tubes,
allowed  to  clot  at  –4°C  for  1 h  and  centrifuged  at
20003 g for 10 min. The obtained serum was divided
into aliqots and stored at –25°C until assayed for IL-6,
LIF , CNTF and sIL-6R. The sera were randomly coded
and testing was carried out without knowledge of the
clinical status of the subject or of related laboratory
data. The cytokine serum concentration was assayed
by  specific,  commercially  available,  enzyme  linked
(ELISA)  assay  kits  (Quantikine,  R&D  Systems  Inc,
USA) in accordance with the manufacturer’s instruc-
tions and analysed with an ELISA reader at 492 mm.
The  procedure  was  described  in  details  else-
where.
19,28 In  brief,  the  monoclonal  antibodies,
specific  for  the  cytokines  were  placed  onto  the
microtitre plates provided with the kits. Standard and
the  samples  were  pipetted  into  the  wells  and  any
present  cytokines  were  bound  by  the immobilizing
antibody. After  rinsing  enzyme  –  linked  polyclonal
antibodies, specific for cytokines, were added to the
wells to sandwich the cytokines immobilized during
the  first  incubation.  After  the  next  rinsing  the
substrate  solution  was  added  to  the  wells  and  the
colour  developed  proportionally  to  the  amount  of
cytokines bound in the first step. In each assay the
appropriate recombinant  human  cytokine was used
to generate the standard curve. The concentration of
cytokines and sIL-6R in the samples were determined
by interpolation from the standard curve. Serum sIL-
6R concentration measurement was diluted 40 times
and its level was measured between 7.8 and 500 pg/
ml. Sensitivity of the assay for IL-6 was 0.7 pg/ml, for
LIF 2.0 pg/ml and for CNTF 8.0 pg/ml.
Statistical analysis
The mean values were compared in Kruskal Wallis and
Mann-Whitney  tests.  Differences  in  parameters
between  the  groups  were  evaluated  with  Student’s
t-test. Statistical analysis for the frequency of detect-
able cytokines was performed using chi-squared test.
The  linear  correlations  between  serum  interleukin
levels  compared  with  each  other  or  with  Ritchie’s
index were evaluated using the Spearman  rank-sum
correlation coefficient and linear regression calculated
with the least-squares method. Results are presented
with R
2 coefficients. Comparison and correlation were
considered significant when P < 0.05.
Results
Table 2 shows the results of measurement of IL-6, LIF ,
CNTF and sIL-6R in the serum of 66 patients with RA
and 24 normal individuals. IL-6, LIF and sIL-6R were
detectable in the serum of all 66 patients with RA. In
contrast, CNTF was measurable only in 15 (22.7%) out
of 66 patients. In the control group IL-6 and sIL-6R
were detectable in all 24 individuals, LIF in 16 (66.7%)
and CNTF only in eight (33.5%). The levels of IL-6 and
sIL-6R  were  higher  in  RA  patients  than  in  healthy
persons (P < 0.001  and P < 0.03 respectively). The
concentrations of IL-6 and sIL-6R were higher in the
patients in Stages 3 and 4 of RA activity than in Stages
1 and 2 RA activity. A detectable level of LIF was also
found in all 66 patients with RA and in 16 out of 24
(66.7%)  normal  individuals.  In  contrast  CNTF  was
measurable only in the sera from 15 out of 66 (22.7%)
patients  with  RA  and  in  eight  out  of  24  (33.3%)
healthy subjects. The mean values of LIF and CNTF in
RA patients  and  normal individuals  were  not statis-
tically different (P > 0.05).  However, LIF was more
frequently  detectable  in  RA  patients  than  in  the
control  group  (P <  0.03).  We  found  a  positive
correlation between IL-6 as well as sIL-6R concentra-
tions and Ritchie’s index (R
2 = 0.1404, P < 0.002 and
R
2 =  0.0952,  P <  0.02,  respectively)  but  no  such
correlation between LIF and CNTF serum levels with
Ritchie’s index (R
2 = 0.0035, P > 0.05 and R
2 = 0.002,
P > 0.05 respectively) (Fig. 1).
We also analysed the relationship between serum
concentrations of IL-6, sIL-6R, LIF and CNTF with the
duration of the disease (Fig. 2). We observed a positive
correlation between these parameters only in the case
of  IL6  (R
2 =  0.1401,  P <  0.002),  but  no  such
correlation in the case of sIL-6R, LIF and CNTF (R
2 =
0.0420,  P > 0.05,  R
2 =  0.0001,  P > 0.05  and  R
2 =
0.0020, P > 0.05 respectively).
The relationship between the serum levels of sIL-6R
with evaluated cytokines, as well as between partic-
ular  cytokines  alone  was  also  analysed (Fig.  3). We
observed  no  correlation  between  any  of  the  com-
pared parameters. The calculation of the ratio of sIL-
6R to  IL-6  in patients with  RA according to  disease
activity is presented in Table 3.
We found a significantly lower ratio of sIL-6R to IL-6
in  RA  patients  compared  with  normal  persons
(1406.3  and  8806.0  respectively).  There  was  also
significant difference between the sIL-6R to IL-6 ratio
in Stages 1 and 2 and Stage 4 RA activity according to
Mallya and Mace (P < 0.05).
The  influence  of  the  treatment  schedule  on  the
serum concentrations of IL-6, sIL-6R, LIF and CNTF has
been also analysed (data not presented). However we
found no statistically significant differences between
the  levels  of  detected  cytokines  or  sIL-6R  in  the
patients treated with NSAID only, prednisone, metho-
trexate, D-penicillamine, gold salts or sulfasalazine.
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The role of cytokines in the pathogenesis of RA and
their significance in clinical monitoring of the disease
advancement has been attacting much attention since
a few years.
3 –6 In this disease the articular synovial
membrane  is  infiltrated  with  inflammatory  cells
diffusing  into  the  synovial  fluid. The  inflammatory
process spreads from the synovial membrane to the
cartilage  and  bone  tissue  causing  their  damage.
3
Cytokines play a crucial role in sustaining an inflam-
matory process within synovial membranese. So far,
most attention has been paid to the role of inflamma-
tory cytokines in RA pathogenesis, especially TNF-a ,
IL-1, IFN-g and  IL-6.
3,5,22 The  activity  of other cyto-
kines constituting IL-6 group, like LIF , OSM and IL-11
in RA was a subject of single reports and the role of
CNTF  in  this  disease  has  not  been  investigated  so
far.
16–18,29 Unlike the soluble TNF receptors the role
of sIL-6R in  RA and  the prognostic meaning of this
receptor are also poorly investigated.
30,31
In our studies we assessed serum concentration of
IL-6, LIF , CNTF and sIL-6R in 66 patients with RA in
different stages of disease advancement and duration
as  well  as  in  24  healthy  controls.  IL-6, sIL-6R  were
detected in the serum of all patients with RA and all
healthy persons. Detectable levels of LIF were found in
all RA patients but only in 16 (66.7%) healthy controls,
and CNTF in 15 (22.7%) patients with RA and eight
(33.3%) individuals from the control group.
The  concentration  of  IL-6  in  blood  serum  of  RA
patients was six-fold higher than in healthy persons
and  correlated  with  the  disease  activity  and  its
duration. These results are consistent with the observa-
tions made by Madhok et al.
32 and van Leeuwen et
al.
33 Moreover,  high  concentration  of  IL-6  in  the
synovial  fluid  of  RA  patients  and  the  correlation
between the concentration of this cytokine and the
intensity of bone lesions seen in radiograms, as well as
its  significant  role  in  the  joint  destruction,  were
demonstrated.
30,34 Also clinical improvement and the
decrease  of  C-reactive  protein  in  the  serum  of  the
T. Robak et al.
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Table 2. Serum levels of IL-6, LIF, CNTF and sIL-6R in patients with RA according to disease activity (according to Mallya and
Mace) and normal control group. Mean values in pg/ml ± SD, median and range in parentheses
Group
cytokines
ALL RA
patients
n = 66
RA
stages 1 & 2
n = 16
RA
stage 3
n = 34
RA
stage 4
n = 16
Normal
control group
n = 24
Statistical
analysis
for means
(a) (b) (c) (d) (e)
IL-6 n1 = 66 n1 = 16 n1 = 34 n1 = 16 n1 = 24
a & e p < 0.001*
Mean ± SD 52.7 ± 53.2 22.5 ± 20.3 52.3 ± 42.2 83.6 ± 77.0 5.1 ± 3.0 b & e p < 0.001*
Median 34.1 12.3 40.9 37.5 5.3 c & e p < 0.001*
Range 1.5–234.0 2.3–58.0 1.5–138.4 5.8–234.0 0.5–16.6 d & e p < 0.001*
b & c p < 0.04*
b & d p < 0.02*
c & d p > 0.05
LIF n1 = 66 n1 = 16 n1 = 34 n1 = 16 n1 = 16
a & e p > 0.05
Mean ± SD 5.1 ± 2.1 5.20 ± 2.1 5.0 ± 1.9 5.2 ± 2.7 3.8 ± 3.4 b & e p > 0.05
Median 4.8 4.8 4.8 4.8 4.0 c & e p > 0.05
Range 0.8–9.6 2.4–9.6 1.6–8.8 0.8–9.6 0.0–10.4 d & e p > 0.05
b & c p > 0.05
b & d p > 0.05
c & d p > 0.05
CNTF n1 = 15 n1 = 3 n1 = 7 n1 = 5 n1 = 8
a & e p > 0.05
Mean ± SD 0.9 ± 3.0 0.49 ± 1.1 1.1 ± 4.0 0.93 ± 1.4 1.17 ± 2.30 b & e p > 0.05
Median 0.0 0.0 0.0 0.0 0.0 c & e p > 0.05
Range 0.0–19.5 0.0–3.9 0.0–19.5 0.0–3.2 0.0–8.5 d & e p > 0.05
b & c p > 0.05
b & d p > 0.05
c & d p > 0.05
sIL-6R n1 = 66 n1 = 16 n1 = 34 n1 = 66 n1 = 24
a & e p < 0.03*
Mean ± SD 49756 ± 14503 40688 ± 10395 50436 ± 13564 57381 ± 15745 41683 ± 11497 b & e p > 0.05
Median 45366 40802 48066 50870 39674 c & e p < 0.04*
Range 17288–81760 17288–62904 31200–79248 40180–15744 23732–64512 d & e p < 0.002*
b & c p < 0.05*
b & d p < 0.003*
c & d p < 0.05*
*Statistically significant difference; n = number of investigated individuals; n1 = number of individuals with detectable cytokines.patients treated with antibodies against CD4+ lympho-
cytes, and then antibodies neutralizing IL-6, may prove
the significance of IL-6 in the pathogenesis of RA.
35
The  results  of  our  studies  may  indicate  that  two
other  cytokines  related  to  IL-6  i.e.  LIF  and  CNTF ,
unlike  IL-6  are  of  smaller  pathogenetic  significance
and  of  no  use  in  determining  RA  activity.  Their
concentration  in  the  serum  of  patients  did  not
correlate  with  the  degree  of  RA  activity  and  was
similar  to  their  serum  concentration  in  healthy
individuals. Our results differ from those reported by
Okamoto et al.
16 who showed that the isolated from
the  synovium  of  RA  patients  cell  produce  greater
quantities  of  LIF  than  patients  with  osteoarthritis,
nevertheless,  they  were  unable  to  detect  this  cyto-
kine  in  blood  serum  of  patients  with  RA.  These
differences  may  stem  from  different  sensitivity  of
ELISA tests applied in both studies. In the studies of
Okamoto  et  al. the  sensitivity  reached  15 pg/ml,
while  in  our  tests  the  sensitivity  was  much  higher
and amounted to 2 pg/ml. High concentration of LIF
in  the  synovial  fluid  of  patients  with  RA  was  also
observed by Waring et al.
17 It should be emphasized
IL-6 type cytokines and sIL-6R in RA
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FIG. 1. Correlation between serum concentrations of IL-6, sIL-
6R, LIF and CNTF with disease activity according to Ritchie’s
index (RI) in patients with rheumatoid arthritis (RA).
FIG. 2. Correlation between serum concentrations of IL-6, sIL-
6R, LIF and CNTF with duration of disease.
FIG. 3. Correlations between serum concentrations of IL-6R
with IL-6, LIF and CNTF, IL-6 with LIF and CNTF and LIF with
CNTF in patients with RA.that  we  detected  LIF  previously  in  the  serum  of
some  SLE  patients  and  the  concentration  of  this
cytokine  correlated  with  the  disease  activity  when
using the same  ELISA  method.
19
Elevated  levels  of  LIF  were  also  observed  in  the
serum  of  patients  with  non-Hodgkin’s  lymphoma,
Hodgkin’s disease, chronic lymphocytic leukaemia as
well  as  in  tissue  shock.
36,37 Although  it  should  be
emphasized that in  those studies the ELISA  method
with polyclonal antirabbit  antibodies was employed,
which is probably  more sensitive than the commer-
cially available tests used in our studies i.e. Quantikine,
R&D Systems Inc. with monoclonal antibodies.
38
To  our  knowledge  CNTF  has  so  far  not  been
assessed in the serum of RA patients. In our studies
this  cytokine  was  detectable  only  in  15  out  of  66
(22.7%)  patients  with  RA  and  in  eight  out  of  24
(33.3%)  of  healthy  individuals.  This  cytokine  was
previously  assessed  by  us  in  SLE  patients,  and  was
present in 52 out of 64 of the examined patients.
19 In
SLE we also demonstrated a correlation between the
concentration of CNTF and the activity of the disease.
It may indicate that CNTF has a greater significance in
the pathogenesis of SLE than in RA.
The  determination  of  the  role  of  IL-6  group
cytokines in the pathogenesis of RA requires further
investigation.  However,  the  already  available  data
indicate that the role of LIF, CNTF, OSM and IL-11 in
the  initializing  and  sustaining  inflammation  is  less
important than the role of IL-6 alone. Gabay et al.
39
showed  that  LIF  and  IL-11  stimulate  human  hep-
atocytes  to produce  the  acute  phase  protein  much
poorer  than  IL-6,  although  in  the  experiments  on
mice it was found that CNTF stimulates production of
the hepatic acute phase proteins to the same extent as
IL-6.
40 It is not clear, however, whether this cytokine
has  a  similar  biological  activity  in  experimental
animals and humans. The results of our research are
consistent with the observations of Okamoto et al.
16
and indicate that despite the functional similarity of
IL-6 group cytokines, IL-6  is in  this group the main
mediator of inflammation in RA.
Soluble IL-6 receptor (sIL-6R), unlike other soluble
cytokine receptors, has the unique property of acting
agonistically with its ligand and enhances the stimula-
tion  of  this  cytokine  on  generating  acute  phase
proteins  (APP)  by human  hepatocytes,
41 as  well  as
proliferation  of  myeloma  cells
42 and  synovial  fibro-
blasts.
43 In our studies we found positive correlation
between  the  serum  concentration  of  sIL-6R  in
patients with RA and Ritchie’s index. We also demon-
strated significantly lower values of sIL-6R/IL-6 ratio in
RA patients than in healthy subjects and lower values
of this index in the most active form of the disease
(Stage 4 of RA activity according to Mallya and Mace)
than in less active forms (Stages 1 and 2). We did not
reveal however, correlation between the concentra-
tions of IL-6 and sIL-6R in the serum of RA patients.
These observations indicate a complex and not very
clear  relation  between  these  two  proteins  in  this
disease.
Studies of Kotake et al. showed higher concentra-
tions  of IL-6  and  sIL-6R  in  the  synovial  fluid  in  RA
patients  than  in  patients  with  osteoarthritis  and
correlation of these peptides with the degree of joint
destruction.
30 Though  contradictory  results  were
obtained in patients with juvenile rheumatoid arthri-
tis, where negative correlation between the concen-
tration of sIL-6R and IL-6 in serum was observed, and
the  concentration  of  sIL-6R  in  those  patients  was
lower than in healthy persons.
44 However it should
be  emphasized  that  the  concentration  of  sIL-6R  in
patients  with SLE, AIDS  and  multiple myeloma was
significantly  higher  than  in  healthy  persons.
42,45
Nevertheless, like in the case of our RA patients, no
correlation between the serum concentration of sIL-
6R and IL-6 was found in multiple myeloma.
46 These
data  indicate  that  different  agents  influencing  the
production  of  both  proteins,  may  be  present  in
different diseases.
In conclusion we can state that the serum concen-
tration of IL-6 and sIL-6R in patients with RA is higher
than in healthy persons, and these peptides may serve
as markers of this disease activity. The concentration
of other cytokines of IL-6 group (LIF and  CNTF) in
serum of RA patients and healthy individuals neither
differs significantly nor correlates with the activity of
the disease.
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Table 3. Serum sIL-6R/II-6 ratio in the patients with RA according to disease activity according to Mallya and Mace
sIL-6R/II-6 ALL RA
patients
n = 66
RA
stages 1 & 2
n = 16
RA
stage 3
n = 34
RA
stage 4
n = 16
Normal
control group
n = 24
Statistical
analysis
for means
(a) (b) (c) (d) (e)
Mean ± SD 4114 ± 7829 4342 ± 4159 4716 ± 10200 2601 ± 4014 12976 ± 16309 a  &  e p < 0.001*
Median 1406.3 3381.5 987.5 1265.7 8806.0 b & e p < 0.001*
Range 206–6357 639–13524 331–46357 205–13852 2988–85816 c & e p < 0.001*
d & e p > 0.005
b & e p < 0.005*
c & d p < 0.05
*Statistically significant difference.References
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